The order of application for PD-1/PD-L1 inhibitors in different cancer types ranging from highest use to lowest use is as follows: lung cancer, liver cancer, melanoma, colorectal cancer, lymphoma, gastric cancer, esophageal cancer, renal cancer, and breast cancer. This evidence concerns the gene PDCD1 and lung cancer.